Research
Hormonal
Retatrutide has the highest adverse event risk among the treatments studied.
Clinicians should be aware of the higher risk of adverse events when prescribing retatrutide.
StrongSupportsmedium confidence
Retatrutide had the highest AE risk.
Why this rating
The study is a Bayesian network meta-analysis.
Source
Efficacy and Safety of <scp>GLP</scp> ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian <scp>NMA</scp>
Binayak Sinha et al. · Obesity · 2025
DOI 10.1002/oby.24360
Meta-analysisCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →